Astellas join Milner Therapeutics Consortium

Astellas join Milner Therapeutics Consortium

We are delighted to announce that Astellas have joined the Milner Therapeutics Consortium as our 11th pharma partner. Astellas, a global pharmaceutical company headquartered in Japan, works across more than 70 countries in the US, Europe and Asia. They bring to the...
Milner Institute announced as finalist for OBN Award

Milner Institute announced as finalist for OBN Award

We are proud to announce that the Milner Therapeutics Institute has been shortlisted for a 2021 OBN Award in the category for Most Impactful Business Support Organisation. The OBN Awards, now in their 13th year, celebrate individuals and life sciences companies that...
Connect: Health Tech is launched

Connect: Health Tech is launched

We are excited to announce that the University of Cambridge has launched the Connect: Health Tech microsite and online community platform, as part of the new University Enterprise Zone (UEZ) initiative. The delivery team behind Connect: Health Tech is the Milner...
Autophagy targets in neurodegeneration

Autophagy targets in neurodegeneration

We are excited to announce a new collaboration which has been set up through the Milner Therapeutics Consortium to investigate autophagy targets in neurodegeneration. This is the first such project to bring together multiple academic groups across the University and...

Pin It on Pinterest